Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipid storage and recombinant HDL in Fabry disease and ASMD
NL-OMON50314Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2017
- Countries
- 1
01
Overview
Open-label trial in Fabry disease (FD) and acid sphingomyelinase deficiency (ASMD) (3 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoints: HDL composition and plasma LCAT activity, LDL receptor activity and abundance and 3 more. Started Jun 2017; status: recruiting.
02
Conditions
Fabry disease (FD)acid sphingomyelinase deficiency (ASMD)
Beyond the preview
Go deeper on NL-OMON50314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50314.